Lôo H, Benkelfat C, Poirier M F, Vanelle J M, Olié J P, Dennis T, Scatton B
Neuropsychobiology. 1986;15(2):62-7. doi: 10.1159/000118243.
Plasma levels of free and conjugated 3,4-dihydroxyphenylethyleneglycol (DOPEG), the main deaminated metabolite of norepinephrine, were assayed in 48 depressed patients before initiating a treatment with either maprotiline, an inhibitor of norepinephrine reuptake, or indalpine, a specific inhibitor of serotonin reuptake. The two groups of depressed patients were comparable. The therapeutic effect was evaluated by using the Hamilton Rating Scale for Depression. No difference in pretreatment plasma free and conjugated DOPEG levels was found between the responders and the nonresponders to maprotiline or indalpine. Neither was there any difference in the pretreatment levels of plasma free DOPEG between the two groups of responders and the two groups of nonresponders to either drug. Finally, there was no difference in the therapeutic response to maprotiline or to indalpine between the patients with high and low plasma DOPEG levels before treatment. These results indicate that there is no relationship between the initial plasma levels of DOPEG in depressed patients and their therapeutic response to a norepinephrine or a serotonin reuptake blocker.
在48名抑郁症患者开始使用去甲肾上腺素再摄取抑制剂马普替林或5-羟色胺再摄取特异性抑制剂吲哚平治疗之前，检测了血浆中去甲肾上腺素的主要脱氨基代谢产物游离和结合的3,4-二羟基苯乙二醇（DOPEG）水平。两组抑郁症患者具有可比性。使用汉密尔顿抑郁评定量表评估治疗效果。对马普替林或吲哚平有反应者和无反应者之间，治疗前血浆游离和结合DOPEG水平无差异。两组对任一药物有反应者和无反应者之间，治疗前血浆游离DOPEG水平也无差异。最后，治疗前血浆DOPEG水平高的患者和低的患者对马普替林或吲哚平的治疗反应无差异。这些结果表明，抑郁症患者初始血浆DOPEG水平与其对去甲肾上腺素或5-羟色胺再摄取阻滞剂的治疗反应之间没有关系。
